Erasca, Inc. Under Investigation for Shareholder Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Source: Globenewswire
- Legal Investigation Launched: Moore Law, PLLC is investigating the officers and directors of Erasca, Inc. for allegedly making false or misleading statements to investors, potentially exposing shareholders to losses.
- Drug Candidate Controversy: Erasca's positive claims regarding its cancer therapy drug ERAS-0015 are alleged to lack a reasonable basis, with improper comparisons to Revolution Medicines' data raising concerns about patent and trade secret violations.
- Significant Market Reaction: Following the disclosure on April 27, 2026, that Erasca received a legal letter from Revolution Medicines, its stock price plummeted from $21.49 to $19.15, reflecting investor concerns about the company's future.
- Shareholder Rights Protection: Affected shareholders can seek monetary damages and corporate governance reforms through Moore Law, with all representation on a contingency fee basis, ensuring no costs to shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 15.050
Low
2.00
Averages
5.50
High
11.00
Current: 15.050
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca, Inc. Under Investigation for Shareholder Claims
- Legal Investigation Launched: Moore Law, PLLC is investigating the officers and directors of Erasca, Inc. for allegedly making false or misleading statements to investors, potentially exposing shareholders to losses.
- Drug Candidate Controversy: Erasca's positive claims regarding its cancer therapy drug ERAS-0015 are alleged to lack a reasonable basis, with improper comparisons to Revolution Medicines' data raising concerns about patent and trade secret violations.
- Significant Market Reaction: Following the disclosure on April 27, 2026, that Erasca received a legal letter from Revolution Medicines, its stock price plummeted from $21.49 to $19.15, reflecting investor concerns about the company's future.
- Shareholder Rights Protection: Affected shareholders can seek monetary damages and corporate governance reforms through Moore Law, with all representation on a contingency fee basis, ensuring no costs to shareholders.
See More
Multiple Companies Face Class Action Lawsuits
- BitGo Lawsuit Overview: BitGo Holdings, Inc. (NYSE:BTGO) faces a class action lawsuit for the period from January 22, 2026, to May 13, 2026, alleging that the company failed to disclose the impact of declining digital asset prices on its financial performance, with a lead plaintiff deadline of August 7, 2026.
- Erasca Legal Issues: Erasca, Inc. (NASDAQ:ERAS) is involved in a class action lawsuit for the period from January 14, 2025, to April 26, 2026, due to undisclosed patent risks from improper comparisons, affecting investor confidence in the company's prospects, with a lead plaintiff deadline of August 10, 2026.
- Nano-X Lawsuit Details: Nano-X Imaging Ltd. (NASDAQ:NNOX) faces a class action lawsuit for the period from March 31, 2025, to April 17, 2026, alleging that the company overstated operational efficiency and product demand, leading to significant operational expenses and cash burn risks, with a lead plaintiff deadline of August 11, 2026.
- Microsoft Allegations: Microsoft Corporation (NASDAQ:MSFT) is involved in a class action lawsuit for the period from May 1, 2025, to January 28, 2026, for failing to disclose multiple issues with its Copilot product line, resulting in a decline in market share, with a lead plaintiff deadline of August 11, 2026.
See More
ClaimsFiler Alerts Investors on Erasca Securities Class Action Deadline
- Lawsuit Background: Erasca, Inc. is facing a securities class action lawsuit for failing to disclose material information between January 14, 2025, and April 26, 2026, which could negatively impact the company's reputation and stock price.
- Product Risks: The lawsuit alleges that the preclinical data for the ERAS-0015 product was based on improper comparisons, potentially exposing Erasca to risks regarding patent and trade secret protections, thereby affecting investor confidence in the company's future.
- Investor Action: ClaimsFiler reminds Erasca investors to file lead plaintiff applications by August 10, 2026, indicating a growing concern among investors regarding corporate governance and transparency.
- Legal Support: Kahn Swick & Foti, LLC offers legal consultations to help investors understand their legal options, reflecting a trend of investors seeking professional support in the face of potential losses.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in its ERAS-0015 product.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, representing investors who purchased shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws that could lead to significant investor losses.
- Intellectual Property Dispute: Despite assurances given to investors in March 2026 regarding the protection of ERAS-0015's intellectual property, Erasca disclosed on April 27 that it received a legal challenge from Revolution Medicines questioning the validity of its claims, further heightening market anxiety.
- Patient Adverse Event: Following treatment with ERAS-0015, a patient suffered an adverse event and died a month later, raising serious concerns about the safety profile of the drug and potentially jeopardizing Erasca's future research and marketing efforts.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Context: The class action lawsuit seeks to represent investors who purchased Erasca stock between January 14, 2025, and April 26, 2026, alleging misleading statements regarding the intellectual property protection of ERAS-0015, potentially violating federal securities laws.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, market reactions intensified, raising further questions about the safety of the company's product and potentially impacting future clinical trials and market acceptance.
- Ongoing Legal Investigation: Hagens Berman is investigating whether Erasca intentionally misled investors, and if confirmed, this could lead to broader legal repercussions and financial losses for the company.
See More
Notice of Securities Class Action Against Erasca, Inc.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, during the class period, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests, especially since the class action has not yet been certified, urging prompt action to safeguard their rights.
See More
Erasca, Inc. Under Investigation for Shareholder Claims
- Legal Investigation Launched: Moore Law, PLLC is investigating the officers and directors of Erasca, Inc. for allegedly making false or misleading statements to investors, potentially exposing shareholders to losses.
- Drug Candidate Controversy: Erasca's positive claims regarding its cancer therapy drug ERAS-0015 are alleged to lack a reasonable basis, with improper comparisons to Revolution Medicines' data raising concerns about patent and trade secret violations.
- Significant Market Reaction: Following the disclosure on April 27, 2026, that Erasca received a legal letter from Revolution Medicines, its stock price plummeted from $21.49 to $19.15, reflecting investor concerns about the company's future.
- Shareholder Rights Protection: Affected shareholders can seek monetary damages and corporate governance reforms through Moore Law, with all representation on a contingency fee basis, ensuring no costs to shareholders.
See More
Multiple Companies Face Class Action Lawsuits
- BitGo Lawsuit Overview: BitGo Holdings, Inc. (NYSE:BTGO) faces a class action lawsuit for the period from January 22, 2026, to May 13, 2026, alleging that the company failed to disclose the impact of declining digital asset prices on its financial performance, with a lead plaintiff deadline of August 7, 2026.
- Erasca Legal Issues: Erasca, Inc. (NASDAQ:ERAS) is involved in a class action lawsuit for the period from January 14, 2025, to April 26, 2026, due to undisclosed patent risks from improper comparisons, affecting investor confidence in the company's prospects, with a lead plaintiff deadline of August 10, 2026.
- Nano-X Lawsuit Details: Nano-X Imaging Ltd. (NASDAQ:NNOX) faces a class action lawsuit for the period from March 31, 2025, to April 17, 2026, alleging that the company overstated operational efficiency and product demand, leading to significant operational expenses and cash burn risks, with a lead plaintiff deadline of August 11, 2026.
- Microsoft Allegations: Microsoft Corporation (NASDAQ:MSFT) is involved in a class action lawsuit for the period from May 1, 2025, to January 28, 2026, for failing to disclose multiple issues with its Copilot product line, resulting in a decline in market share, with a lead plaintiff deadline of August 11, 2026.
See More
ClaimsFiler Alerts Investors on Erasca Securities Class Action Deadline
- Lawsuit Background: Erasca, Inc. is facing a securities class action lawsuit for failing to disclose material information between January 14, 2025, and April 26, 2026, which could negatively impact the company's reputation and stock price.
- Product Risks: The lawsuit alleges that the preclinical data for the ERAS-0015 product was based on improper comparisons, potentially exposing Erasca to risks regarding patent and trade secret protections, thereby affecting investor confidence in the company's future.
- Investor Action: ClaimsFiler reminds Erasca investors to file lead plaintiff applications by August 10, 2026, indicating a growing concern among investors regarding corporate governance and transparency.
- Legal Support: Kahn Swick & Foti, LLC offers legal consultations to help investors understand their legal options, reflecting a trend of investors seeking professional support in the face of potential losses.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in its ERAS-0015 product.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, representing investors who purchased shares between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws that could lead to significant investor losses.
- Intellectual Property Dispute: Despite assurances given to investors in March 2026 regarding the protection of ERAS-0015's intellectual property, Erasca disclosed on April 27 that it received a legal challenge from Revolution Medicines questioning the validity of its claims, further heightening market anxiety.
- Patient Adverse Event: Following treatment with ERAS-0015, a patient suffered an adverse event and died a month later, raising serious concerns about the safety profile of the drug and potentially jeopardizing Erasca's future research and marketing efforts.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating severe market concerns regarding the safety and intellectual property of its products.
- Lawsuit Context: The class action lawsuit seeks to represent investors who purchased Erasca stock between January 14, 2025, and April 26, 2026, alleging misleading statements regarding the intellectual property protection of ERAS-0015, potentially violating federal securities laws.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, market reactions intensified, raising further questions about the safety of the company's product and potentially impacting future clinical trials and market acceptance.
- Ongoing Legal Investigation: Hagens Berman is investigating whether Erasca intentionally misled investors, and if confirmed, this could lead to broader legal repercussions and financial losses for the company.
See More
Notice of Securities Class Action Against Erasca, Inc.
- Class Action Notice: Rosen Law Firm reminds investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: Erasca, along with its CEO and CFO, is accused of violating federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, during the class period, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise and success in this field.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests, especially since the class action has not yet been certified, urging prompt action to safeguard their rights.
See More
